H.C. Wainwright initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $9 price target Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRDL:
- Cardiol Therapeutics Announces AGM Results and New Board Member
- Cardiol Therapeutics Reports Q1 2025 Financial Results
- Cardiol Therapeutics to Webcast AGM Amidst Ongoing Clinical Trials
- Promising Clinical Developments and Investment Potential in Cardiol Therapeutics
- Promising Prospects for Cardiol Therapeutics: Buy Rating Backed by Strong Market Potential and Innovative Treatment Developments